AIVIS, a leading innovator in medical artificial intelligence (AI), has enhanced its global presence in the healthcare technology landscape by winning the Silver Award at the 2025 Edison Awards, held on April 3^rd in Fort Myers, Florida. The award recognizes PathoAiD®-Thyroid Dx, AIVIS’s AI-powered pathology solution for thyroid cancer diagnosis.

Developed to address the challenges of uncertainty and misdiagnosis in thyroid nodule evaluation, the award-winning solution leverages AI to directly analyze slide images of thyroid tissue. Unlike traditional diagnostic methods, it rapidly and accurately distinguishes between benign and malignant nodules. This capability is expected to greatly reduce unnecessary surgeries and alleviate the burden on patients. Additionally, PathoAiD®-Thyroid Dx offers a cost-effective alternative to expensive molecular tests—cutting diagnostic costs by up to 80%—and reduces the typical diagnostic timeline from over four weeks to just a few minutes. This not only demonstrates technological superiority but also delivers proven economic and social benefits.

The Edison Awards are a globally respected event that honors the legacy of the renowned inventor Thomas Edison. Winners are selected based on criteria including innovation, technological excellence, market potential, and social impact. AIVIS’s PathoAiD®-Thyroid Dx met these standards and received strong acclaim from the judging panel.

In conjunction with this achievement, AIVIS also presented two key research studies at the 2025 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, held from March 22 to 27 at the Boston Convention Center. These studies demonstrated the high clinical potential of the AI technology behind the award-winning product. Notably, the AI-generated heatmaps showed a strong correlation with regions identified by human pathologists, further validating the system’s reliability and reinforcing its international credibility.

AIVIS CEO Lee Dae-Hong commented

“The Edison Awards are a global benchmark for both technological innovation and social value. Winning this award proves that our thyroid cancer diagnostic AI solution is competitive on the world stage. Moving forward, we aim to lead AI-driven innovation in precision medicine and actively promote the excellence of Korean medical technology in the global pathology community.”

Leveraging the Edison Award, AIVIS plans to actively pursue global market expansion by leveraging opportunities such as global healthcare partnerships and investment attraction. The company also intends to accelerate technological innovation to further advance the field of precision medicine.

About AIVIS

AIVIS is a South Korea-based medical AI company driving innovation in digital pathology. Its flagship solution, Qanti IHC, provides automated quantification of key biomarkers—including ER, PR, HER2, and Ki-67—with exceptional capability in detecting HER2-low and ultralow cases. Backed by MFDS approval and a growing global presence, AIVIS is dedicated to advancing diagnostic accuracy and enabling AI-powered precision medicine worldwide.